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South Korea’s social security system is a social insur-
ance system similar to those in France, Germany,
Japan, and Taiwan [1]. By law, South Korean citizens
are covered by health insurance. In addition, health-
care providers must contract with the National Health
Insurance Corporation. This uniﬁed social health
insurance system provides almost all South Koreans
with health insurance.
During the last 50 years, medical breakthroughs
and signiﬁcant health-care advances have improved
the quality of health care and the management of
disease and chronic illness. With this progress has
come markedly increased health-care costs. Currently,
these expenditures are exceeding Korea’s economic
growth rate [2]. Consequently, there has been a signiﬁ-
cant amount of research on the rational use of health-
care resources and interest in other countries’ means of
controlling costs [3].
Prioritization of reimbursement has become a major
issue within South Korea’s national health insurance
system. The current presiding principle behind reim-
bursement is that all medically necessary health-care
services are covered and reimbursed with the exception
of those on the negative or noncovered list of health-
care technologies.
Health-care policymakers decide whether a technol-
ogy is medically appropriate for patients and therefore
reimbursed as daily practice or not. Health-care
decision-making for what are considered medically
appropriate health-care services has been based on
opinion or opinion-based information. Because reim-
bursement decisions are opinion-based, they are not
only subjective, but can be signiﬁcantly delayed by
dissenting opinion [4].
Consequently, evidence-based medicine consisting
of clinical expertise and patient preferences or values
combined with clinical research is being introduced to
make health-care decisions reasonably, objectively, and
clearly as well as to reduce conﬂicts among stakehold-
ers [5–7]. This process, combined with considera-
tion of affordability, should improve reimbursement
decisions.
The Health Insurance Review & Assessment
Service (HIRA) also utilizes scientiﬁc evidence in the
decision-making process. HIRA’s goal is to maintain
and improve national health through health-care
review and quality assessment. HIRA is responsible
for reviewing medical fees and evaluating at what
level and cost health-care services are delivered to
beneﬁciaries [8]. In addition to health-care services
review and evaluation, HIRA supports government
coverage decisions and pricing.
Since 2006, the evidence-based decision-making
system has been introduced progressively. An Evidence
Based Review Manual, with methods of appropriate
questioning, searching, extracting data, classiﬁcation
of articles, and presentation, has been used by HIRA
for policy coverage.
Another challenging issue for policymakers is the
uncertainty with regard to how much improvement
in health-care quality can be expected with the intro-
duction of expensive new health technology. To
address this issue, the South Korean National Assem-
bly passed legislation that allows heath technology
assessment of new health technologies, with the
exception of medications. Because this legislation is
not part of the Health Insurance Act, health-care
providers are not obligated to apply health technol-
ogy assessment (HTA) to new technologies, but if
HTA reports become mandatory for reimbursement,
it is likely to become a requirement.
The legislature is establishing an advisory commit-
tee for new health technology assessment review
(NHTAC) and a special subcommittee responsible for
systemic literature review and draft reports. NHTAC
will conduct the ﬁnal review of the new technology
and state the results of assessment based on its two
major criteria for health technology assessment, safety
and effectiveness.
For medications, Korean FDA (KFDA) focuses on
safety and efﬁcacy. Although there is a strong need for
drug evaluation based on effectiveness and cost-
effectiveness, the review process for new health tech-
nologies does not include new medications. However,
South Korea has introduced pharmacoeconomic
analysis for drug evaluation in the health insurance
decision-making process.
South Korea has a relatively higher cost and growth
rate of pharmaceutical expenditure than other coun-
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tries [9]. While incorporating evidence-based decision-
making into the health-care system will lower costs,
South Korea will need to follow steps such as those
taken in the United States, where efforts have been
made to reduce variation and standardize what is con-
sidered “medical necessity” in health-care decision-
making [10,11]. South Korea will need to ﬁnd
consensus on deﬁning what is “medically necessary”
for its citizens’ health care.
In conclusion, the health-care system in South
Korea has been experiencing issues that are similar to
those of other developed countries, such as the need
for rational use of health-care resources, continuous
improvement in the quality of health care, and patient
safety. Evidence-based decision-making and health
technology assessment are two major ways to achieve
these goals. These methods incorporate quality patient
care based on scientiﬁc evidence versus opinion, and
base decisions on the country’s values and what the
country can afford to pay.
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